Catabasis Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Catabasis Pharmaceuticals's estimated annual revenue is currently $12.7M per year.
- Catabasis Pharmaceuticals's estimated revenue per employee is $155,000
- Catabasis Pharmaceuticals's total funding is $283M.
Employee Data
- Catabasis Pharmaceuticals has 82 Employees.
- Catabasis Pharmaceuticals grew their employee count by 32% last year.
Catabasis Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP, General Counsel | Reveal Email/Phone |
2 | Executive Director, Medical Affairs | Reveal Email/Phone |
3 | Chief Financial Officer | Reveal Email/Phone |
4 | Senior Administrative Associate | Reveal Email/Phone |
Catabasis Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Catabasis Pharmaceuticals?
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) Linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART LinkerSM platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates. For more information on the Company's drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com.
keywords:N/A
$283M
Total Funding
82
Number of Employees
$12.7M
Revenue (est)
32%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Catabasis Pharmaceuticals News
Aegerion Pharmaceuticals, Catabasis Pharmaceuticals, Isis Pharmaceuticals, Novartis AG, uniQure N.V.. This comprehensive Type I Hyperlipoproteinemia Drug...
... Glutamyltransferase 2 Market Size 2022 Segments, Competitors Strategy, Regional Analysis, Key Players |Catabasis Pharmaceuticals Inc, Zedira GmbH,,.
Adverum Biotechnologies Inc, BioMarin Pharmaceutical Inc., ... Catabasis Pharmaceuticals Inc., Forward Pharma A/S, Ixchel Pharma LLC,...
2020 ANNUAL REPORT Dear Shareholders, While the past year has been a period of change for Catabasis, our commitment to bringing hope with life- changing therapies to patients and families remains the same. We recently acquired Quellis Biosciences, including our lead program QLS-215, a potentia ...
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, acquired Quellis Biosciences, a biopharmaceutical company focused on discovering new molecules to treat serious rare diseases. The private placement is expected to result in gross proceeds to Catabasis of approximately ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $11.9M | 82 | -44% | $19.5M |
#2 | $12.7M | 82 | -41% | N/A |
#3 | $11.9M | 82 | N/A | N/A |
#4 | $22.1M | 82 | 19% | $25.6M |
#5 | $11.5M | 82 | -9% | N/A |